Intensity Therapeutics Reports Q3 Results and Resumption of Clinical Trials

Filing content

Intensity Therapeutics reported its third quarter 2026 financial results and announced the resumption of patient enrollment in its INVINCIBLE-3 and INVINCIBLE-4 clinical trials. The company also raised $1.5 million in net proceeds through its ATM facility during the third quarter.